All In Biotech

Free tool

FAERS Monitor: Nerlynx

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208051 or its brand name (Nerlynx, Neratinib Maleate). Reports on generic versions are filed under their own applications.

Reports

2,319

Serious

1,373

59% of reports

Hospitalization

685

Death reported

364

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,262
  • nausea557
  • fatigue474
  • off label use414
  • vomiting317
  • constipation279
  • decreased appetite257
  • death199
  • disease progression157
  • dehydration148
  • weight decreased139
  • abdominal pain119
  • headache116
  • asthenia104
  • dizziness103

Reports by year received

View as table
YearReports
20093
201023
201110
201213
201316
20148
20155
20161
2017143
2018739
2019241
2020255
2021280
2022170
2023147
2024124
202584
202657

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
diarrhoeaSignal1,26217.817.120,541
disease progressionSignal15712.010.41,587
constipationSignal27911.610.42,721
dehydrationSignal14810.18.61,207
decreased appetiteSignal25710.09.02,105
nauseaSignal5576.45.92,622
vomitingSignal3176.15.51,382
fatigueSignal4745.55.11,818
abdominal painSignal1194.63.9340
weight decreasedSignal1394.53.8382
off label useSignal4144.33.91,086
astheniaSignal1042.52.195
deathSignal1992.11.8118
dizziness1031.91.642
headache1161.71.432

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.